智通财经网·2026-02-10 09:45Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Chaohui Pharmaceutical Co., Ltd., has received acceptance for the drug registration application of Benzocaine Gel by the National Medical Products Administration, indicating progress in the company's product pipeline [1] Group 1: Product Development - The drug is a self-developed chemical product intended for topical anesthesia, suitable for adults and infants over one month old [1] - The cumulative R&D investment for this drug is approximately RMB 7.19 million (unaudited) as of December 2025 [1] Group 2: Market Potential - According to IQVIA CHPA, the sales revenue of Benzocaine Gel in mainland China (excluding Hong Kong, Macau, and Taiwan) is projected to be around RMB 443 million in 2024 [1]